Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.
Management Board
Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.
Previous CEO of Intercell, Managing Director for Novartis Vaccines & Diagnostics Germany, Vice President of Global Industrial Operations at Chiron Vaccines, more than 25 years in the vaccine industry.
Previous CEO and co-founder of Vivalis, formerly responsible for Groupe Grimaud’s development in Asia, 25 years in corporate business development and life sciences.
Senior international positions in various Pharmaceutical/ Biotech organizations, including GlaxoSmithKline, Celsion, Grünenthal and Daiichi Sankyo, strong expertise in Medical Affairs and Clinical Development, as well as Global Market Access, 20 years of experience in life sciences.
Supervisory Board
As part of Valneva’s corporate governance system, the Supervisory Board, acting in the interests of the shareholders, participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.
Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.
Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.
Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.
Member of the Supervisory Board, Partner at MVM Partners LLP, Qualified as chartered accountant with PWC’s Private Equity and Venture Capital practice. Board member of eZono AG, Onbone Oy and Patient Connect Ltd.
Scientific Advisory Board
Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.
Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda
President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices
Professor of International Health at the Johns Hopkins Bloomberg School of Public Health, Principal Investigator at the Center for Immunization Research
Board member of Amryt Pharma, Supervisory Board member of OxThera AB, Zealand Pharma A/S, former SVP for international development at Sanofi, former SVP of the pharmaceutical division at Fournier Laboratories
Adjunct Professor of Medicine at Johns Hopkins University, Co-founder and Board Member of Affinivax, Board Member of Genocea, former Supervisory Board Member of Crucell and former Executive Vice President and CSO of Wyeth Vaccines
Emeritus Professor, Wistar Institute, University of Pennsylvania, Former director of the division of infectious diseases at Children’s Hospital of Philadelphia, associate Chairman of the department of pediatrics at the University of Pennsylvania and Medical Director at Sanofi Pasteur
